Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation

MLA

Xu-Ying Pei, et al. “Letermovir Prophylaxis for Cytomegalovirus Is Associated with Risk of Post-Transplant Lymphoproliferative Disorders after Haploidentical Stem Cell Transplantation.” Haematologica, vol. 999, no. 1, Nov. 2024. EBSCOhost, https://doi.org/10.3324/haematol.2024.286265.

APA

Xu-Ying Pei, Qiang Huang, Ling-Jie Luo, Hai-Lu Sun, Jing Liu, Yu-Qian Sun, Xiao-Dong Mo, Meng Lv, Dai-Hong Liu, Hong-Yan Ma, Yan-Wei Wu, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Liang Chen, & Xiao-Jun Huang. (2024). Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation. Haematologica, 999(1). https://doi.org/10.3324/haematol.2024.286265

Chicago

Xu-Ying Pei, Qiang Huang, Ling-Jie Luo, Hai-Lu Sun, Jing Liu, Yu-Qian Sun, Xiao-Dong Mo, et al. 2024. “Letermovir Prophylaxis for Cytomegalovirus Is Associated with Risk of Post-Transplant Lymphoproliferative Disorders after Haploidentical Stem Cell Transplantation.” Haematologica 999 (1). doi:10.3324/haematol.2024.286265.